Brief: Sentynl Therapeutics And Mereo Biopharma Announce Option And License Agreement For Alvelestat In Alpha-1 Antitrypsin Deficiency-Associated Lung Disease
11/08/2026 14:13
BRIEF-Sentynl Therapeutics And Mereo Biopharma Announce Option And License Agreement For Alvelestat In Alpha-1 Antitrypsin Deficiency-Associated Lung Disease Aug 11 (Reuters) - Mereo Biopharma Group PLC MAH0y.F:
SENTYNL THERAPEUTICS AND MEREO BIOPHARMA ANNOUNCE OPTION AND LICENSE AGREEMENT FOR ALVELESTAT IN ALPHA-1 ANTITRYPSIN DEFICIENCY-ASSOCIATED LUNG DISEASE (AATD-LD)
SENTYNL THERAPEUTICS- SENTYNL AND MEREO ENTER OPTION AND LICENSE AGREEMENT FOR ALVELESTAT IN AATD-LD
SENTYNL THERAPEUTICS- ON OPTION EXERCISE, SENTYNL TO COMMERCIALIZE ALVELESTAT IN U.S.; MEREO RETAINS REST OF WORLD RIGHTS
SENTYNL THERAPEUTICS- MEREO TO RECEIVE UP TO $40 MILLION IN PAYMENTS AND DOUBLE-DIGIT TIERED ROYALTIES ON U.S. SALES
Source text: ID:nPnbBXbDKa
Further company coverage: [MAH0y.F]
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mereo BioPharma
See all newsBrief: Sentynl Therapeutics And Mereo Biopharma Announce Option And License Agreement For Alvelestat In Alpha-1 Antitrypsin Deficiency-Associated Lung Disease
UK's Mereo BioPharma Q2 loss narrows on lower R&D spending
Brief: Mereo BioPharma Q2 Operating Income USD -7.03 Million
Brief: Mereo BioPharma Q1 Net Income USD -6.719 Million
Brief: Mereo BioPharma FY Revenue USD 500 Thousand Vs. IBES Estimate USD 520 Thousand